Clin2
NCT06249867Possibly a fitRecruiting

Darifenacin for ALS: safety and effect

Amyotrophic Lateral Sclerosis

Part of Brain & nervous system, Hormones & metabolism clinical trials.

This trial tests whether darifenacin, a drug currently used for bladder control, can safely help people with ALS. It aims to understand how the drug works in the body and if it can slow the disease or relieve symptoms.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
30 people
Ages
18 years to 85 years
Study type
Interventional

Who can take part

  • You have a confirmed diagnosis of ALS (probable or definite).
  • You are between 18 and 85 years old.
  • Your ALS symptoms started less than 3 years ago.
  • Your breathing is at least half of normal (FVC ≥ 50%).
  • You can swallow tablets whole.
  • You must be willing to use effective birth control if you or your partner could become pregnant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07325591Not yet recruiting· Phase 2/Phase 3
Testing tazbentetol for ALS safety and effectiveness

This trial tests whether a drug called tazbentetol can help people with ALS. It aims to see if it is safe and slows the disease's progression.

NCT07221240Recruiting· Phase 1
Amisodin safety study for healthy adults with ALS

This trial tests a new drug called Amisodin in healthy adults who also have ALS. It checks if the drug is safe and how the body processes it.

Baltimore, Maryland
NCT06126315Recruiting· Phase 2/Phase 3
Testing acetyl-L-carnitine in early ALS

This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.

Sydney
NCT05407324Recruiting· Phase 2
Dazucorilant for ALS patients at higher risk of faster progression

This Phase 2 study tests whether dazucorilant can slow or improve outcomes in people with amyotrophic lateral sclerosis (ALS) who are likely to progress more quickly. You may be able to join if you meet specific ALS type and risk-score requirements and your health tests and medications fit the study rules.

Phoenix, Arizona
NCT07414212Recruiting· Phase 1/Phase 2
Testing EH-301 and NAC with Riluzole for ALS

This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.

San Sebastián, Guipuzcoa
NCT06513546Not yet recruiting· Phase 1/Phase 2
Testing a new drug (PLL001) for early-stage ALS

This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and if it can slow the progression of the disease. You may be a good fit if you have been recently diagnosed and are still in the early stages of ALS.

Hear when a new Amyotrophic Lateral Sclerosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.